Shiga toxin glycosphingolipid receptors and their lipid membrane ensemble in primary human blood-brain barrier endothelial cells

Glycobiology

Volumn 27, Issue 1, 2017, Pages 99-109

  Legros, Nadine ^a   Dusny, Stefanie ^a   Humpf, Hans Ulrich ^a   Pohlentz, Gottfried ^a   Karch, Helge ^a   Müthing, Johannes ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Detergent resistant membranes; Glycolipids; Lipid rafts; Lyso phosphatidylcholine; Primary human brain microvascular endothelial cells; Sphingomyelin

Indexed keywords

FLOTILLIN 2; SHIGA TOXIN; SHIGA TOXIN GLYCOSPHINGOLIPID RECEPTOR; SPHINGOMYELIN; UNCLASSIFIED DRUG; ANTIBODY; CELL SURFACE RECEPTOR; CERAMIDE TRIHEXOSIDE; GLOBOSIDE; GLOBOTETRAOSYLCERAMIDE; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID; SHIGELLA TOXIN RECEPTOR; VEROTOXIN 1; VEROTOXIN 2;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CELL MEMBRANE; CONTROLLED STUDY; DENSITY GRADIENT; DENSITY GRADIENT CENTRIFUGATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; IMMUNODETECTION; IN VITRO STUDY; LIPID MEMBRANE; LIPID RAFT; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SUCROSE GRADIENT; THIN LAYER CHROMATOGRAPHY; WESTERN BLOTTING; CHEMISTRY; ENDOTHELIUM CELL; ESCHERICHIA COLI; GENETICS; MEMBRANE MICRODOMAIN; METABOLISM; PATHOGENICITY;

ANTIBODIES; BLOOD-BRAIN BARRIER; CHROMATOGRAPHY, THIN LAYER; ENDOTHELIAL CELLS; ESCHERICHIA COLI; GLOBOSIDES; GLYCOSPHINGOLIPIDS; HUMANS; MEMBRANE MICRODOMAINS; RECEPTORS, CELL SURFACE; SHIGA TOXIN 1; SHIGA TOXIN 2; TRIHEXOSYLCERAMIDES;

EID: 85014397173     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cww090     Document Type: Article

References (83)

1. Barras A, Martin FA, Bande O, Baumann JS, Ghigo JM, Boukherroub R, Beloin C, Siriwardena A, Szunerits S. 2013. Glycan-functionalized diamond nanoparticles as potent E. coli anti-adhesives. Nanoscale. 5:2307-2316.
2. Bauwens A, Bielaszewska M, Kemper B, Langehanenberg P, von Bally G, Reichelt R, Mulac D, Humpf HU, Friedrich AW, Kim KS, et al. 2011. Differential cytotoxic actions of Shiga toxin 1 and Shiga toxin 2 on microvascular and macrovascular endothelial cells. Thromb Haemost. 105:515-528.
3. Bauwens A, Betz J, Meisen I, Kemper B, Karch H, Müthing J. 2013. Facing glycosphingolipid-Shiga toxin interaction: Dire straits for endothelial cells of the human vasculature. Cell Mol Life Sci. 70:425-457.
4. Betz J, Bielaszewska M, Thies A, Humpf HU, Dreisewerd K, Karch H, Kim KS, Friedrich AW, Müthing J. 2011. Shiga toxin glycosphingolipid receptors in microvascular and macrovascular endothelial cells: Differential association with membrane lipid raft microdomains. J Lipid Res. 52:618-634.
5. Betz J, Dorn I, Kouzel IU, Bauwens A, Meisen I, Kemper B, Bielaszewska M, Mormann M, Weymann L, Sibrowski W, et al. 2016. Shiga toxin of enterohaemorrhagic Escherichia coli directly injures developing human erythrocytes. Cell Microbiol. doi:10.1111/cmi.12592.
6. Bielaszewska M, Karch H. 2005. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost. 94:312-318.
7. Brigotti M, Alfieri R, Sestili P, Bonelli M, Petronini PG, Guidarelli A, Barbieri L, Stirpe F, Sperti S. 2002. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells. FASEB J. 16:365-372.
8. Brigotti M, Carnicelli D, Arfilli V, Tamassia N, Borsetti F, Fabbri E, Tazzari PL, Ricci F, Pagliaro P, Spisni E, et al. 2013. Identification of TLR4 as the receptor that recognizes Shiga toxin in human neutrophils. J Immunol. 191:4748-4758.
9. Brown DA, Rose JK. 1992. Sorting of GPI-anchored proteins to glycolipidenriched membrane subdomains during transport to the apical cell surface. Cell. 68:533-544.
10. Brown DA. 2006. Lipid rafts, detergent-resistant membranes, and raft targeting signals. Physiology. 21:430-439.
11. Carnicelli D, Arfilli V, Ricci F, Velati C, Tazzari PL, Brigotti M. 2016. The antibiotic polymyxin B impairs the interactions between Shiga toxins and human neutrophils. J Immunol. 196:1177-1185.
12. Carquin M, D'Auria L, Pollet H, Bongarzone ER, Tyteca D. 2015. Recent progress on lipid lateral heterogeneity in plasma membranes: From rafts to submicrometric domains. Prog Lipid Res. 62:1-24.
13. Chester MA. 1998. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycolipids-recommendations 1997. Eur J Biochem. 257:293-298.
14. Chien YY, Jan MD, Adak AK, Tzeng HC, Lin YP, Chen YJ, Wang KT, Chen CT, Chen CC, Lin CC. 2008. Globotriose-functionalized gold nanoparticles as multivalent probes for Shiga-like toxin. ChemBioChem. 9:1100-1109.
15. Chinnapen DJ, Chinnapen H, Saslowsky S, Lencer WI. 2007. Rafting with cholera toxin: Endocytosis and trafficking from plasma membrane to ER. FEMS Microbiol Lett. 266:129-137.
16. Ciana A, Achilli C, Minetti G. 2014. Membrane rafts of the human red blood cell. Mol Membr Biol. 31:47-57.
17. Cooling LL, Walker KE, Gille T, Koerner TA. 1998. Shiga toxin binds to human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid. Infect Immun. 66:4355-4366.
18. Distler U, Souady J, Hülsewig M, Drmić-Hofman I, Haier J, Friedrich AW, Karch H, Senninger N, Dreisewerd K, Berkenkamp S, et al. 2009. Shiga toxin receptor Gb3Cer/CD77: Tumor association and promising therapeutic target in pancreas and colon cancer. PLoS One. 4:e6813.
19. Dittmer JC, Lester RL. 1964. A simple, specific spray for the detection of phospholipids on thin-layer chromatograms. J Lipid Res. 15:126-127.
20. Domon B, Costello CE. 1988a. Structure elucidation of glycosphingolipids and gangliosides using high-performance tandem mass spectrometry. Biochemistry. 27:1534-1543.
21. Domon B, Costello CE. 1988b. A systematic nomenclature for carbohydrate fragmentation in FAB-MS/MS spectra of glycoconjugates. Glycoconj J. 5:397-409.
22. Eisenhauer PB, Chaturvedi P, Fine RE, Ritchie AJ, Pober JS, Cleary TG, Newburg DS. 2001. Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin. Infect Immun. 69:1889-1894.
23. Eisenhauer PB, Jacewicz MS, Conn KJ, Koul O, Wells JM, Fine RE, Newburg DS. 2004. Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells. Microb Pathog. 36:189-196.
24. Ergonul Z, Hughes AK, Kohan DE. 2003. Induction of apoptosis of human brain microvascular endothelial cells by Shiga toxin 1. J Infect Dis. 187:154-158.
25. Fujinaga Y, Wolf AA, Rodighiero C, Wheeler H, Tsai B, Allen L, Jobling MG, Rapoport T, Holmes RK, Lencer WI. 2003. Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulum. Mol Biol Cell. 14:4783-4793.
26. Ghosh SA, Polanowska-Grabowska RK, Fujii J, Obrig T, Gear AR. 2004. Shiga toxin binds to activated platelets. J Thromb Haemost. 2:499-506.
27. Gupta G, Surolia A. 2010. Glycosphingolipids in microdomain formation and their spatial organization. FEBS Lett. 584:1634-1641.
28. Hanada K. 2005. Sphingolipids in infectious diseases. Jpn J Infect Dis. 58:131-148.
29. Head BP, Patel HH, Insel PA. 2014. Interaction of membrane/lipid rafts with the cytoskeleton: Impact on signaling and function: Membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim Biophys Acta. 1838:532-545.
30. Hoffmann P, Hülsewig M, Duvar S, Ziehr H, Mormann M, Peter-Katalinić J, Friedrich AW, Karch H, Müthing J. 2010. On the structural diversity of Shiga toxin glycosphingolipid receptors in lymphoid and myeloid cells determined by nanoelectrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 24:2295-2304.
31. Jansson L, Ångström J, Lebens M, Imberty A, Varrot A, Tenebrg S. 2010. Carbohydrate binding specificities and crystal structure of the cholera toxin-like B-subunit from Citrobacter freundii. Biochimie. 92:482-490.
32. Kanda T, Ariga T, Kubodera H, Jin HL, Owada K, Kasama T, Yamawaki M, Mizusawa H. 2004. Glycosphingolipid composition of primary cultured human brain microvsacular endothelial cells. J Neurosci Res. 78:141-150.
33. Karch H, Tarr PI, Bielaszewska M. 2005. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol. 295:405-418.
34. Karlsson KA. 1995. Microbial recognition of target-cell glycoconjugates. Curr Opin Struct Biol. 5:622-635.
35. Khan F, Proulx F, Lingwood CA. 2009. Detergent-resistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted haemolytic uremic syndrome pathology. Kidney Int. 75:1209-1216.
36. Klotzsch E, Schütz GJ. 2013. A critical survey of methods to detect plasma membrane rafts. Philos Trans R Soc Lond B Biol Sci. 368:20120033.
37. Komura N, Suzuki KGN, Ando H, Konishi M, Koikeda M, Imamura A, Chadda R, Fujiwara TK, Tsuboi H, Sheng R, et al. 2016. Raft-based interactions of gangliosides with a GPI-anchored receptor. Nat Chem Biol. 12:402-410.
38. Kouzel IU, Pohlentz G, Storck W, Radamm L, Hoffmann P, Bielaszewska M, Bauwens A, Cichon C, Schmidt AM, Mormann M, et al. 2013. Association of Shiga toxin glycosphingolipid receptors with membrane microdomains of toxin-sensitive lymphoid and myeloid cells. J Lipid Res. 54:692-710.
39. Lencer WI, Saslowsky D. 2005. Raft trafficking of AB5 subunit bacterial toxins. Biochim Biophys Acta. 1746:314-321.
40. Levery SB. 2005. Glycosphingolipid structural analysis and glycosphingolipidomics. Methods Enzymol. 405:300-369.
41. Lingwood CA, Binnington B, Manis A, Branch DR. 2010. Globotriaosyl ceramide receptor function-Where membrane structure and pathology intersect. FEBS Lett. 584:1879-1886.
42. Lingwood D, Simons K. 2007. Detergent resistance as a tool in membrane research. Nat Protoc. 2:2159-2165.
43. Lingwood D, Simons K. 2010. Lipid rafts as a membrane-organizing principle. Science. 327:46-50.
44. Meisen I, Friedrich AW, Karch H, Witting U, Peter-Katalinic J, Müthing J. 2005. Application of combined high-performance thin-layer chromatography immunostaining and nanoelectrospray ionization quadrupole timeof-flight tandem mass spectrometry to the structural characterization of high- and low-affinity binding ligands of Shiga toxin 1. Rapid Commun Mass Spectrom. 19:3659-3665.
45. Meisen I, Mormann M, Müthing J. 2011. Thin-layer chromatography, overlay technique and mass spectrometry: A versatile triad advancing glycosphingolipidomics. Biochim Biophys Acta. 1811:875-896.
46. Meisen I, Rosenbrück R, Galla HJ, Hüwel S, Kouzel IU, Mormann M, Karch H, Müthing J. 2013. Expression of Shiga toxin 2e glycosphingolipid receptors of primary porcine brain endothelial cells and toxin-mediated breakdown of the blood-brain barrier. Glycobiology. 23:745-759.
47. Mochalin VN, Shenderova O, Ho D, Gogotsi Y. 2012. The properties and applications of nanodiamonds. Nat Nanotechnol.. 7:11-23.
48. Morris RJ, Jen A, Warley A. 2011. Isolation of nano-meso scale detergent resistant membrane that has properties expected of lipid 'rafts'. J Neurochem. 116:671-677.
49. Müthing J. 1998. TLC in structure and recognition studies of glycosphingolipids. In: Hounsell EF, editor. Methods in molecular biology Totowa, NJ, USA, Humana Press Inc. p. 183-195.
50. Müthing J, Radloff M. 1998. Nanogram detection of phospholipids on thinlayer chromatograms. Anal Biochem. 257:67-70.
51. Müthing J, Schweppe CH, Karch H, Friedrich AW. 2009. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb Haemost. 101:252-264.
52. Müthing J, Distler U. 2010. Advances on the compositional analysis of glycosphingolipids combining thin-layer chromatography with mass spectrometry. Mass Spectrom Rev. 29:425-479.
53. Müthing J, Meisen I, Zhang W, Bielaszewska M, Mormann M, Bauerfeind R, Schmidt MA, Friedrich AW, Karch H. 2012. Promiscuous Shiga toxin 2e and its intimate relationship to Forssman. Glycobiology. 22:849-862.
54. Nangaku M, Nishi H, Fujita T. 2007. Pathogenesis and progress of thrombotic microangiopathy. Clin Exp Nephrol. 11:107-114.
55. Obrig TG, Karpman D. 2012. Shiga toxin pathogenesis: Kidney complications and renal failure. Curr Top Microbiol Immunol. 357:105-136.
56. Porubsky S, Federico G, Müthing J, Jennemann R, Gretz N, Büttner S, Obermüller N, Jung O, Hauser IA, Gröne E, et al. 2014. Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure. J Pathol. 234:120-133.
57. Prinetti A, Loberto N, Chigorno V, Sonnino S. 2009. Glycosphingolipid behaviour in complex membranes. Biochim Biophys Acta. 1788:184-193.
58. Ramegowda B, Samuel JE, Tesh VL. 1999. Interaction of Shiga toxins with human brain microvascular endothelial cells: Cytokines as sensitizing agents. J Infect Dis. 180:1205-1213.
59. Richards A, Kavanagh D. 2009. Pathogenesis and thrombotic microangiopathy: Insights from animal models. Nephron Exp Nephrol. 113:e97-e103.
60. Róg T, Vattulainen I. 2014. Cholesterol, sphingolipids, and glycolipids: What do we know about their role in raft-like membranes? Chem Phys Lipids. 184:82-104.
61. Sandvig K, Bergan J, Dyve AB, Skotland T, Torgersen ML. 2010. Endocytosis and retrograde transport of Shiga toxin. Toxicon. 56:1181-1185.
62. Scheutz F, Teel LD, Beutin L, Piérard D, Buvens G, Karch H, Mellmann A, Caprioli A, Tozzoli R, Morabito S, et al. 2012. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stxs nomenclature. J Clin Microbiol. 50:2951-2963.
63. Schweppe CH, Bielaszewska M, Pohlentz G, Friedrich AW, Büntemeyer H, Schmidt MA, Kim KS, Peter-Katalinic J, Karch H, Müthing J. 2008. Glycosphingolipids in vascular endothelial cells: Relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity. Glycoconj J. 25:291-304.
64. Schweppe CH, Hoffmann P, Nofer JR, Pohlentz G, Mormann M, Karch H, Friedrich AW, Müthing J. 2010. Neutral glycosphingolipids in human blood: A precise mass spectrometry analysis with special reference to lipoprotein-associated Shiga toxin receptors. J Lipid Res. 51:2282-2294.
65. Sestili P, Alfieri R, Carnicelli D, Martinelli C, Barbieri L, Stirpe F, Bonelli M, Petronini PG, Brigotti M. 2005. Shiga toxin 1 and ricin inhibit the repair of H2O2-induced DNA single strand breaks in cultured mammalian cells. DNA Repair. 4:271-277.
66. Sharon N. 2006. Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim Biophys Acta. 1760:527-537.
67. Simons K, Gerl MJ. 2010. Revitalizing membrane rafts: New tools and insights. Nat Rev Mol Cell Biol. 11:688-699.
68. Smith HW, Linggood MA. 1971. The transmissible nature of enterotoxin production in human enteropathogenic strain of Escherichia coli. J Med Microbiol. 4:301-305.
69. Smith DC, Lord JM, Roberts LM, Johannes L. 2004. Glycosphingolipids as toxin receptors. Semin Cell Dev Biol. 15:397-408.
70. Smith DC, Sillence DJ, Falguières T, Jarvis RM, Johannes L, Lord JM, Platt FM, Roberts LM. 2006. The association of Shiga-like toxin with detergentresistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect. Mol Biol Cell. 17:1375-1387.
71. Sonnino S, Aureli M, Mauri L, Ciampa MG, Prinetti A. 2015. Membrane lipid domains in the nervous system. Front Biosci (Landmar Ed). 20:280-302.
72. Souady J, Soltwisch J, Dreisewerd K, Haier J, Peter-Katalinić J, Müthing J. 2009. Structural profiling of individual glycosphingolipids in a single thin-layer chromatogram by multiple sequential immunodetection matched with direct IR-MALDI-o-TOF mass spectrometry. Anal Chem. 81:9481-9492.
73. Steil D, Schepers CL, Pohlentz G, Legros N, Runde J, Humpf HU, Karch H, Müthing J. 2015. Shiga toxin glycosphingolipid receptors of Vero-B4 kidney epithelial cells and their membrane microdomain lipid environment. J Lipid Res. 56:2322-2336.
74. Storck W, Meisen I, Gianmoena K, Pläger I, Kouzel IU, Bielaszewska M, Haier J, Mormann M, Humpf HU, Karch H, et al. 2012. Shiga toxin glycosphingolipid receptor expression and toxin susceptibility of human pancreatic ductal adenocarcinomas of differing origin and differentiation. Biol Chem. 393:785-799.
75. Stricklett PK, Hughes AK, Ergonul Z, Kohan DE. 2002. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J Infect Dis. 186:976-982.
76. Strockbine NA, Marques LR, Newland JW, Smith HW, Holmes RK, O'Brien AD. 1986. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun. 53:135-140.
77. Tarr PI, Gordon CA, Chandler WL. 2005. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 365:1073-1086.
78. Teneberg S, Ångström J, Ljungh A. 2004. Carbohydrate recognition by enterohemorrhagic Escherichia coli: Characterization of a novel glycosphingolipid from cat small intestine. Glycobiology. 14:187-196.
79. Trachtman H, Austin C, Lewinski M, Stahl RA. 2012. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol. 8:658-669.
80. Tsai HM. 2006. The molecular biology of thrombotic microangiopathy. Kidney Int. 70:16-23.
81. Vieira FS, Corrêa G, Einicker-Lamas M, Coutinho-Silva R. 2010. Host-cell lipid rafts: A safe door for micro-organisms? Biol Cell. 102:391-407.
82. Zheng XL, Sadler JE. 2008. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol. 3:249-277.
83. Zoja C, Buelli S, Morigi M. 2010. Shiga toxin-associated hemolytic uremic syndrome: Pathophysiology of endothelial dysfunction. Pediatr Nephrol. 25:2231-2240.